SEARCH

SEARCH BY CITATION

References

  • 1
    Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704709.
  • 2
    Simon D, Nolte I, Eberle N, et al. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 2006;20:948954.
  • 3
    Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy for canine lymphoma. J Vet Intern Med 1993;7:289295.
  • 4
    Khanna C, Lund EM, Redic KA, et al. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma. J Am Vet Med Assoc 1998;213:985990.
  • 5
    Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000;14:120124.
  • 6
    Boyce KL, Kitchell BE. Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000;36:395403.
  • 7
    Myers NC, Moore AS, Rand WM, et al. Evaluation of a multidrug chemotherapy protocol (ACOPA-II) in dogs with lymphoma. J Vet Intern Med 1997;11:333339.
  • 8
    Moore AS, Leveille CR, Reimann KA, et al. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest 1995;13:475479.
  • 9
    Bergman PJ, Ogilvie GK, Powers BE. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: Sequential analysis and predictive ability in dogs with lymphoma. J Vet Intern Med 1996;10:354359.
  • 10
    Lee JJ, Hughes CS, Fine RL, et al. P-glycoprotein expression in canine lymphoma: A relevant, intermediate model of multidrug resistance. Cancer 1996;77:18921898.
  • 11
    Tew KD, Colvin OM, Chabner BA. Alkylating agents. In: ChabnerBA, LongoDL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice, 3rd ed. Philadelphia: Lippincott, Williams & Wilkins; 2001:374414.
  • 12
    Moore AS, London CA, Wood CA, et al. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med 1999;13:395398.
  • 13
    Lemarié SL, Eddlestone SM. Treatment of cutaneous T-cell lymphoma with dacarbazine in a dog. Vet Dermatol 1997;8:4146.
  • 14
    Gray KN, Raulston GL, Gleiser CA, et al. Histologic classification as an indicator of therapeutic response in malignant lymphoma in dogs. J Am Vet Med Assoc 1984;184:814817.
  • 15
    Van Vechten M, Helfand SC, Jeglum KA. Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine. J Vet Intern Med 1990;4:187191.
  • 16
    Simon R, Korn EL. Selecting drug combinations based on total equivalent dose (dose intensity). J Natl Cancer Inst 1990;82:14691476.
  • 17
    Korn EL, Simon R. Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. J Clin Oncol 1993;11:794801.
  • 18
    Veterinary co-operative oncology group common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Compar Oncol 2004;2:195213.
  • 19
    Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:601605.
  • 20
    Fan TM, Kitchell BE. Dacarbazine. Comp Contin Ed 2000;22:10201023.
  • 21
    Day RS. Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy. Cancer Res 1986;46:38763885.
  • 22
    Frei E III, Elias A, Wheeler C, et al. The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity. Clin Cancer Res 1998;4:20272037.
  • 23
    Boyer MJ, Tannock IF. Cellular and molecular basis of drug treatment for cancer. In: TannockIF, HillRP, BristowRG, HarringtonL, eds. The Basic Science of Oncology, 4th ed. New York: McGraw-Hill; 2005:349375.
  • 24
    LeBlanc A, Mauldin G, Milner R, et al. Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma. Vet Compar Oncol 2006;4:2132.
  • 25
    Saba CF, Thamm DH, Vail DM. Combination chemotherapy with l-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. J Vet Intern Med 2007;21:127132.
  • 26
    Hahn KA, Barnhill MA, Freeman KP, et al. Detection and clinical significance of plasma glutathione-S-transferases in dogs with lymphoma. In Vivo 1999;13:173175.
  • 27
    Morrison-Collister KE, Rassnick KM, Northrup NC, et al. A combination chemotherapy protocol with MOPP and CCNU consolidation (Tufts VELCAP-SC) for the treatment of canine lymphoma. Vet Compar Oncol 2003;1:180190.
  • 28
    Williams LE, Rassnick KM, Power HT, et al. CCNU in the treatment of canine epitheliotropic lymphoma. J Vet Intern Med 2006;20:136143.
  • 29
    Risbon RE, De Lorimier LP, Skorupski K, et al. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): A retrospective study of 46 cases (1999–2004). J Vet Intern Med 2006;20:13891397.
  • 30
    Kristal O, Rassnick KM, Gliatto JM, et al. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. J Vet Intern Med 2004;18:7580.
  • 31
    Trepanier LA, Danhof R, Toll J, et al. Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides. J Vet Intern Med 2003;17:647652.
  • 32
    Skorupski KA, Clifford CA, Paoloni MC, et al. CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med 2007;21:121126.